Twin Tree Management LP Decreases Stake in Illumina, Inc. $ILMN

Key Points

• Twin Tree Management LP significantly reduced its stake in Illumina, Inc. by 68.2%, selling 33,196 shares to end up with 15,504 shares valued at approximately $1.23 million.
• Illumina's current market capitalization is $15.36 billion, with a stock price range between $68.70 and $156.66 over the past year.
• Wall Street analysts generally rate Illumina's stock as "Hold," with a consensus target price of $123.17, reflecting mixed sentiments toward its future performance.

Twin Tree Management LP lowered its stake in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 68.2% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 15,504 shares of the life sciences company's stock after selling 33,196 shares during the period. Twin Tree Management LP's holdings in Illumina were worth $1,230,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of the business. Baird Financial Group Inc. grew its stake in shares of Illumina by 1,324.9% in the first quarter. Baird Financial Group Inc. now owns 412,348 shares of the life sciences company's stock worth $32,716,000 after purchasing an additional 383,409 shares during the last quarter. Vident Advisory LLC grew its stake in shares of Illumina by 22.4% in the first quarter. Vident Advisory LLC now owns 121,609 shares of the life sciences company's stock worth $9,648,000 after purchasing an additional 22,261 shares during the last quarter. WPG Advisers LLC bought a new stake in shares of Illumina in the first quarter worth about $58,000. State of Wyoming grew its stake in shares of Illumina by 17.5% in the first quarter. State of Wyoming now owns 6,366 shares of the life sciences company's stock worth $505,000 after purchasing an additional 950 shares during the last quarter. Finally, Topline Capital Management LLC bought a new stake in shares of Illumina in the first quarter worth about $2,158,000. 89.42% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the company. Daiwa Capital Markets cut Illumina from an "outperform" rating to a "neutral" rating and set a $94.00 price objective on the stock. in a research report on Tuesday, August 12th. Canaccord Genuity Group boosted their price objective on shares of Illumina from $99.00 to $105.00 and gave the stock a "hold" rating in a report on Friday, August 1st. Scotiabank lowered shares of Illumina from a "sector outperform" rating to a "sector perform" rating and set a $125.00 target price for the company. in a research note on Friday, July 11th. Evercore ISI boosted their price objective on shares of Illumina from $116.00 to $128.00 and gave the company an "outperform" rating in a research report on Tuesday, July 8th. Finally, Wall Street Zen downgraded shares of Illumina from a "buy" rating to a "hold" rating in a report on Saturday, August 2nd. Six analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have given a Sell rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $123.06.

Illumina Trading Up 1.7%

Shares of NASDAQ:ILMN traded up $1.61 during trading on Thursday, reaching $97.68. 1,137,554 shares of the company were exchanged, compared to its average volume of 2,287,629. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.81 and a quick ratio of 1.41. The business's fifty day simple moving average is $99.47 and its 200-day simple moving average is $88.58. Illumina, Inc. has a 12-month low of $68.70 and a 12-month high of $156.66. The firm has a market capitalization of $15.01 billion, a PE ratio of 12.36, a P/E/G ratio of 2.25 and a beta of 1.43.

Illumina (NASDAQ:ILMN - Get Free Report) last released its quarterly earnings data on Thursday, July 31st. The life sciences company reported $1.19 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.02 by $0.17. Illumina had a net margin of 29.36% and a return on equity of 28.93%. The firm had revenue of $1.06 billion for the quarter, compared to the consensus estimate of $1.12 billion. During the same period last year, the firm earned $0.36 earnings per share. The company's quarterly revenue was down 4.8% on a year-over-year basis. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. On average, research analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.